NovaBay Expands Avenova’s Online Distribution

Walmart.com joins Amazon.com and Avenova.com in offering Avenova, the only facial spray confirmed through independent laboratory testing to kill the SARS-CoV-2 virus

EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay^® Pharmaceuticals, Inc. (NYSE American: NBY) announces the launch of Avenova^® on Walmart.com, increasing the availability of its unique facial sanitizer confirmed through independent laboratory testing to kill the SARS-CoV-2 virus on hard surfaces. Avenova, used since 2015 for eyelid and eyelash cleansing, is FDA-cleared, completely non-toxic and gentle enough for daily use on the sensitive skin around the eyes, nose and mouth.

“Avenova has always demonstrated the ability to kill a wide variety of pathogens, and we now have laboratory results proving it as a COVID-killer on hard surfaces,” said Justin Hall, NovaBay’s CEO. “Yet, Avenova is safe for use on delicate facial skin around the eyes, nose and mouth.

“Avenova is formulated with our pure, FDA-cleared hypochlorous acid,” he explained. “Not all hypochlorous acid products are designed for daily use on skin. Additionally, most hypochlorous acid products are not pharmaceutical grade and may not maintain a sufficiently high concentration of hypochlorous acid to kill the virus like Avenova.

“The availability of Avenova through online retail giant Walmart is a major win for NovaBay and our customers,” added Mr. Hall. “We continue to view online sales as the greatest growth channel for Avenova, particularly as pandemic-concerned consumers shift to buying more products online.”

More than 120 million Americans visit walmart.com every month, discovering and buying an enormous number of products. Walmart.com is listed as No. 3 in Digital Commerce 360’s Top 1000 retailers.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics^®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX^® family of products and the AGANOCIDE^® compounds. The Neutrox family of products includes AVENOVA^® for the eye care market, CELLERX^® for the aesthetic dermatology market and NEUTROPHASE^® for the wound care market. The Aganocide compounds, still under development, have target applications in dermatology and urology.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our pandemic related marketing strategies as well as any effect that these marketing activities may have on the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the Company’s cash needs, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website

Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email [e-mail].
www.Avenova.com